Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia.
OBJECTIVE
To explore angiogenic factor differences in preeclamptic patients according to the absence or presence of underlying vascular disease.


METHODS
We prospectively compared serum soluble fms-like tyrosine kinase 1 (sFlt1), soluble endoglin, and placental growth factor (PlGF) from 41 normal-risk and 32 high-risk (preexisting conditions) subjects at serial gestational ages.


RESULTS
Median sFlt1 was lower at delivery in preeclamptic patients with underlying chronic hypertension and/or chronic proteinuria (5115 pg/ml) compared with normal risk preeclamptic patients (16375 pg/ml). PlGF was consistently low in patients who developed preeclampsia.


CONCLUSIONS
Effects of sFlt1 may be contextual, varying according to the health or disease state of vascular endothelium.
Dwyer
Bonnie K
BK
Department of Obstetrics and Gynecology, Santa Clara Valley Medical Center, 751 S. Bascom Ave., San Jose, CA 95128, USA. dwyerbk@gmail.com
Krieg
Sacha
S
Balise
Raymond
R
Carroll
Ian R
IR
Chueh
Jane
J
Nayak
Nihar
N
Druzin
Maurice
M
D000328:Adult; D015703:Antigens, CD / Q000097:blood / Q000378:metabolism; D016022:Case-Control Studies; D000071063:Endoglin; D005260:Female; D005865:Gestational Age; D006801:Humans; D008137:Longitudinal Studies; D000072483:Placenta Growth Factor; D011225:Pre-Eclampsia / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism*; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000097:blood / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000097:blood / Q000378:metabolism; D012307:Risk Factors; D012995:Solubility; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood / Q000378:metabolism*
D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D011956:Receptors, Cell Surface; D000072483:Placenta Growth Factor; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1